PHIO.NASDAQPhio Pharmaceuticals CORP

Form 4: Phio Pharmaceuticals CEO Buys 5,000 Shares

Sentiment:

Statement of Changes in Beneficial Ownership

📋All filings for Phio Pharmaceuticals CORP
🔒Login to Follow

Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, purchased 5,000 shares of common stock at $1.14 per share.

Better than expectedThe purchase of shares by a key executive, especially the CEO, is generally viewed as a positive indicator of management's belief in the company's valuation and future performance.

Summary

  • Robert J. Bitterman, Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, acquired 5,000 shares of common stock.
  • The transaction occurred on November 21, 2025, at a price of $1.14 per share.
  • Following this purchase, Mr. Bitterman beneficially owns a total of 281,421 shares of Phio Pharmaceuticals Corp. common stock.
  • The reported beneficial ownership includes shares of common stock underlying unvested restricted stock units.
  • The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The insider purchase by the CEO indicates a positive sentiment from management regarding the company's future, which is generally a bullish signal for investors.

Positives

  • An insider purchase by the Chairman, President, and CEO signals confidence in the company's future prospects.
  • The acquisition of 5,000 shares at $1.14 per share increases the CEO's direct stake in the company.

Related Party Transactions

  • Robert J. Bitterman, an insider (Director, Officer, 10% Owner), purchased 5,000 shares of Phio Pharmaceuticals Corp. common stock.

Stakeholder Impact

  • Shareholders may view the CEO's purchase as a sign of confidence in the company's future, potentially leading to increased investor interest and positive sentiment.

Key Dates

DateDescription
11/21/2025Date of transaction for the acquisition of common stock by Robert J. Bitterman.
11/24/2025Date the Form 4 was filed with the SEC.

Recommendation

buy

An insider purchase by the Chairman, President, and CEO, particularly when made under a Rule 10b5-1 plan, often signals strong confidence in the company's current valuation and future prospects. While this single transaction doesn't guarantee future performance, it suggests that those closest to the company believe the stock is undervalued or poised for growth, making it a positive signal for potential investors.

Keywords

Phio Pharmaceuticals, PHIO, Insider Buy, Stock Purchase, CEO, Robert J. Bitterman, Form 4, Beneficial Ownership, Equity Securities

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.